QSAR MODELING AND MOLECULAR DOCKING OF BIOLOGICALLY ACTIVE COMPOUNDS FOR PREDICTION OF ANTICANCER ACTIVITY
Keywords:
QSAR; molecular docking; anticancer activity; EGFR; quinazoline; multiple linear regression; applicability domain; computer-aided drug design.Abstract
This study presents a reproducible quantitative structure-activity relationship (QSAR) re-analysis and a structure-based molecular docking framework for predicting anticancer activity of quinazoline derivatives targeting the epidermal growth factor receptor (EGFR). A literature-derived dataset of 31 quinazoline EGFR inhibitors was used, with 26 compounds assigned to model development and five compounds retained as an external test set. Two interpretable descriptors, the frontier-orbital energy gap (EGap) and calculated boiling point (BP), were fitted by multiple linear regression. The independently refitted equation was pIC50 = -29.181 + 3.753(EGap) + 0.03089(BP). The model showed R2 = 0.745, adjusted R2 = 0.722, leave-one-out Q2 = 0.669, training RMSE = 0.740, external R2 = 0.883, and external RMSE = 0.490. Y-randomization (1000 permutations) produced a mean randomized R2 of 0.085, supporting non-random structure-activity association. A Williams plot indicated that all training compounds were within the leverage threshold (h* = 0.346) and standardized residual limits of ±3. Molecular docking was interpreted against the crystallographic EGFR-erlotinib complex (PDB 1M17) and published docking/molecular-dynamics benchmarks. The combined ligand-based and structure-based analysis indicates that electronic structure and thermophysical properties are informative predictors of EGFR inhibitory potency, while ATP-pocket complementarity provides a mechanistic basis for prioritizing quinazoline candidates for experimental testing.
References
1. Moussaoui, M., Baammi, S., Soufi, H., Baassi, M., Salah, M., El Allali, A., Mohammed, B. E., Daoud, R., & Belaaouad, S. (2024). Design and optimization of quinazoline derivatives as potent EGFR inhibitors for lung cancer treatment: A comprehensive QSAR, ADMET, and molecular modeling investigation. ACS Omega, 9(46), 45842-45857. https://doi.org/10.1021/acsomega.4c04639
2. Golbraikh, A., & Tropsha, A. (2002). Beware of q2! Journal of Molecular Graphics and Modelling, 20(4), 269-276. https://doi.org/10.1016/S1093-3263(01)00123-1
3. Tropsha, A., Gramatica, P., & Gombar, V. K. (2003). The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR & Combinatorial Science, 22(1), 69-77. https://doi.org/10.1002/qsar.200390007
4. OECD. (2014). Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models (OECD Series on Testing and Assessment No. 69). OECD Publishing. https://doi.org/10.1787/9789264085442-en
5. Gramatica, P. (2007). Principles of QSAR models validation: Internal and external. QSAR & Combinatorial Science, 26, 694-701. https://doi.org/10.1002/qsar.200610151
6. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455-461. https://doi.org/10.1002/jcc.21334
7. Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of Biological Chemistry, 277, 46265-46272. https://doi.org/10.1074/jbc.M207135200
8. Noolvi, M. N., & Patel, H. M. (2013). A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design. Journal of Saudi Chemical Society, 17(4), 361-379. https://doi.org/10.1016/j.jscs.2011.04.017
9. Ibrahim, M. T., Uzairu, A., Uba, S., & Shallangwa, G. A. (2020). Computational modeling of novel quinazoline derivatives as potent epidermal growth factor receptor inhibitors. Heliyon, 6(2), e03289. https://doi.org/10.1016/j.heliyon.2020.e03289
10. Emami, L., Sabet, R., Khabnadideh, S., Faghih, Z., & Thayori, P. (2021). Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies. Research in Pharmaceutical Sciences, 16(5), 528-546. https://doi.org/10.4103/1735-5362.323919
11. Asadollahi-Baboli, M. (2016). In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors. Molecular Diversity, 20(3), 729-739. https://doi.org/10.1007/s11030-016-9672-0
12. Tu, Y., et al. (2017). Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Bioorganic & Medicinal Chemistry, 25(12), 3148-3157. https://doi.org/10.1016/j.bmc.2017.04.001
13. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26. https://doi.org/10.1016/S0169-409X(00)00129-0
14. Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615-2623. https://doi.org/10.1021/jm020017n
15. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
